share_log

CASI Pharmaceuticals Analyst Ratings

CASI Pharmaceuticals Analyst Ratings

CASI 製藥分析師評級
Benzinga ·  2023/11/15 07:39
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating
11/15/2023 191.26% HC Wainwright & Co. $10 → $12 Maintains Buy
08/14/2023 142.72% HC Wainwright & Co. → $10 Reiterates Buy → Buy
05/22/2023 142.72% HC Wainwright & Co. → $10 Reiterates Buy → Buy
11/16/2022 142.72% BTIG $21 → $10 Maintains Buy
11/15/2022 142.72% HC Wainwright & Co. $12 → $10 Maintains Buy
08/15/2022 191.26% HC Wainwright & Co. $3 → $12 Maintains Buy
06/03/2022 409.71% BTIG $4 → $21 Maintains Buy
05/16/2022 -27.18% HC Wainwright & Co. $4 → $3 Maintains Buy
05/18/2021 -2.91% BTIG → $4 Initiates Coverage On → Buy
05/14/2021 -2.91% HC Wainwright & Co. $3.5 → $4 Maintains Buy
04/26/2021 -7.77% Mizuho → $3.8 Initiates Coverage On → Buy
10/23/2020 21.36% Oppenheimer → $5 Initiates Coverage On → Outperform
03/24/2020 -15.05% HC Wainwright & Co. $7 → $3.5 Maintains Buy
日期 上行/下行 分析師事務所 目標價格變動 評級變動 之前/當前的評級
11/15/2023 191.26% HC Wainwright & Co. 10 美元 → 12 美元 維護 購買
08/14/2023 142.72% HC Wainwright & Co. → 10 美元 重申 購買 → 購買
05/22/2023 142.72% HC Wainwright & Co. → 10 美元 重申 購買 → 購買
11/16/2022 142.72% BTIG 21 美元 → 10 美元 維護 購買
11/15/2022 142.72% HC Wainwright & Co. 12 美元 → 10 美元 維護 購買
08/15/2022 191.26% HC Wainwright & Co. 3 美元 → 12 美元 維護 購買
06/03/2022 409.71% BTIG 4 美元 → 21 美元 維護 購買
05/16/2022 -27.18% HC Wainwright & Co. 4 美元 → 3 美元 維護 購買
05/18/2021 -2.91% BTIG → 4 美元 啓動覆蓋範圍開啓 → 購買
05/14/2021 -2.91% HC Wainwright & Co. 3.5 美元 → 4 美元 維護 購買
04/26/2021 -7.77% 瑞穗市 → 3.8 美元 啓動覆蓋範圍開啓 → 購買
10/23/2020 21.36% 奧本海默 → 5 美元 啓動覆蓋範圍開啓 → 跑贏大盤
2020 年 3 月 24 日 -15.05% HC Wainwright & Co. 7 美元 → 3.5 美元 維護 購買

What is the target price for CASI Pharmaceuticals (CASI)?

CASI 製藥(CASI)的目標價格是多少?

The latest price target for CASI Pharmaceuticals (NASDAQ: CASI) was reported by HC Wainwright & Co. on November 15, 2023. The analyst firm set a price target for $12.00 expecting CASI to rise to within 12 months (a possible 191.26% upside). 4 analyst firms have reported ratings in the last year.

HC Wainwright & Co. 於2023年11月15日公佈了CASI製藥(納斯達克股票代碼:CASI)的最新目標股價。該分析公司將目標股價設定爲12.00美元,預計CASI將在12個月內上漲至12美元(可能上漲191.26%)。去年有4家分析公司公佈了評級。

What is the most recent analyst rating for CASI Pharmaceuticals (CASI)?

CASI製藥(CASI)的最新分析師評級是多少?

The latest analyst rating for CASI Pharmaceuticals (NASDAQ: CASI) was provided by HC Wainwright & Co., and CASI Pharmaceuticals maintained their buy rating.

CASI製藥(納斯達克股票代碼:CASI)的最新分析師評級由HC Wainwright公司提供,CASI製藥維持買入評級。

When is the next analyst rating going to be posted or updated for CASI Pharmaceuticals (CASI)?

CASI製藥(CASI)的下一個分析師評級何時發佈或更新?

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CASI Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CASI Pharmaceuticals was filed on November 15, 2023 so you should expect the next rating to be made available sometime around November 15, 2024.

分析師在進行了廣泛的研究後得出了股票評級,其中包括瀏覽公開財務報表,與CASI Pharmicals的高管和客戶交談,以及聽取業績電話會議。大多數分析師每三個月進行一次評級,因此每家公司每年應獲得4個評級。CASI Pharmicals的最新評級是在2023年11月15日提交的,因此您應該預計下一個評級將在2024年11月15日左右公佈。

Is the Analyst Rating CASI Pharmaceuticals (CASI) correct?

分析師評級CASI Pharmicals(CASI)是否正確?

While ratings are subjective and will change, the latest CASI Pharmaceuticals (CASI) rating was a maintained with a price target of $10.00 to $12.00. The current price CASI Pharmaceuticals (CASI) is trading at is $4.12, which is out of the analyst's predicted range.

儘管評級是主觀的,並將發生變化,但最新的CASI製藥公司(CASI)評級維持不變,目標股價爲10.00美元至12.00美元。CASI製藥(CASI)目前的交易價格爲4.12美元,超出了分析師的預測區間。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論